- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04707833
Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen (SeroCOV)
Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen
At present, the offer of tests for the serological diagnosis of CoVID-19 (detection of IgG, IgM or IgA antibodies against CoV-2 SARS) is plethoric and is based on the use of a very large number of rapid diagnostic unit tests, a few dedicated high throughput automated systems or reagents on existing open systems. The offer will continue to expand in the coming months.
In order to meet the objectives mentioned by the Prime Minister, and confirmed in the HAS report of April 16, 2020 and in the opinion n°6 of the COVID-19 scientific council concerning the potential use of these serological tests at the end of the COVID-19 epidemic, the Virology laboratory wishes to validate the sensitivity and specificity of the tests it intends to use.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Christophe Plantier, Professor
- Phone Number: 02 32 88 66 72
- Email: Jc.plantier@chu-rouen.fr
Study Locations
-
-
-
Rouen, France, 760031
- Recruiting
- Rouen university hospital
-
Contact:
- David Mallet
-
Contact:
- Email: secretariat.dcr@chu-rouen.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The inclusion criteria in the retrospective "Negative/Potentially Interfering" group are as follows :
- Adult patient sampled prior to the onset of the COVID-19 epidemic (before January 2020)
- Patient presenting a coronavirus infection other than SARS-CoV-2, or other respiratory viral infections (influenza, metapneumovirus)
- Patients for whom a serum is kept in the biocollection declared under the number AC-2014-2293 and kept in the Institute of Clinical Biology, University Hospital of Rouen.
The criteria for inclusion in the "acute point infection" group are as follows:
- Patients screened by a positive RT-PCR for an SARS-CoV-2 infection
- Patients aged ≥ 18 years old
- Patients taken in charge in the emergency room / in a unit / in COVID resuscitation at the Rouen University Hospital.
- Patients having read and understood the briefing note
- Non-opposition to participation in the study
The criteria for inclusion in the "Sequential acute infection" group are as follows:
- Patients with positive RT-PCR for CoV-2-SARS infection
- Patients aged ≥ 18 years old
- Taken care of in a COVID unit at the Rouen University Hospital
- Having read and understood the briefing note and signed the informed consent form
The criteria for inclusion in the "Convalescent" group are as follows:
- Caregivers working at the UH of Rouen
- Screened by positive RT-PCR for SARS-CoV-2 infection,
- Healed for at least one month at the time of inclusion
- Having read and understood the briefing note and signed the informed consent form
Exclusion Criteria:
- Minor person
- Known Pregnancy
- Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection / subtutorship or guardianship
- Person not affiliated with social security
- Person who does not understand and speak French
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient infected or cured from covid19
|
The tests used will be the following: EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of immunological Abbott Architect SARS-CoV-2 IgG Assay
Time Frame: 24 months
|
Measurement of antibodies against COVID-19 infection (Sensitivity and specificity )
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of immunological of EUROIMMUN SARS-CoV-2(IgA) ELISA, EUROIMMUN SARS-CoV-2 (IgG) ELISA, WANTAI SARS-CoV-2 Ab ELISA, WANTAI SARS-CoV-2 IgM ELISA, Diasorin LIAISON SARS CoV-2 S1/S2 IgG, Roche ECL anti-SARS-Cov-2 (combined IgG IgA)
Time Frame: 24 months
|
Measurement of antibodies against COVID-19 infection (Sensitivity and specificity )
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020/0126/HP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corona Virus Infection
-
Ain Shams UniversityMisr International UniversityCompletedCorona Virus Infection | Corona Virus Disease 19 (Covid19) | Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)Egypt
-
Montreal Heart InstituteNational Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation and other collaboratorsTerminatedCorona Virus InfectionSpain, United States, Canada, Brazil, Greece, South Africa
-
ANRS, Emerging Infectious DiseasesSciences Economiques et Sociales de la Santé & Traitement de l'Information... and other collaboratorsWithdrawn
-
National Institute of Allergy and Infectious Diseases...CompletedCorona Virus InfectionUnited States
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Investigación Biomédica de SalamancaTerminated
-
The Cleveland ClinicCompletedCOVID | Corona Virus InfectionUnited States
-
NeurognosUnknownCOVID | Corona Virus Infection | SARS-CoV2Chile
-
University of Sao PauloMaria Aparecida de Andrade Moreira Machado; Thais Marchini de Oliveira ValarelliNot yet recruitingCorona Virus Infection | Exposure During Pregnancy
-
Chronic Obstructive Pulmonary Disease Trial Network...TerminatedVirus Diseases | Corona Virus Infection | Infection ViralDenmark
-
National Research Center for Cardiac Surgery, KazakhstanNazarbayev University Medical CenterRecruitingCovid19 | Corona Virus InfectionKazakhstan
Clinical Trials on Serological testing for COVID-19 infection
-
Central Hospital, Nancy, FranceCompletedSmoking BehaviorsFrance
-
Centre Hospitalier Intercommunal CreteilCompleted
-
Assiut UniversityCompletedCOVID-19 | Cataract SurgeryEgypt
-
University of AberdeenNot yet recruitingCovid19 | Pulmonary Embolism
-
Rigshospitalet, DenmarkCompleted
-
Scripps Translational Science InstituteCue HealthRecruitingImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised IndividualsHIV Infections | Lymphoma | Leukemia | Cancer | Multiple Myeloma | Immunosuppression | Immunodeficiency | Transplant | Graft Versus Host Disease | Age-Related ImmunodeficiencyUnited States
-
International Centre for Diarrhoeal Disease Research...Columbia UniversityCompletedSchool AbsenteeismBangladesh
-
Centre Hospitalier Universitaire de NiceCompleted
-
Shiraz University of Medical SciencesCompletedCOVID-19 Pandemic | Dyspnea; Cardiac | Chest Syndrome | Functional Cardiac DisorderIran, Islamic Republic of
-
Centre integre universitaire de sante et de services...Université de MontréalCompletedCovid19 | Death | Elderly Infection | Infection Viral | Infections, Respiratory | Infection, Coronavirus | Old Age; Dementia | Epidemic DiseaseCanada